Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HER2-positive breast cancer (confirmed by a recent biopsy).
- You must not have received chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer before.
- You can have had hormone therapy for metastatic disease (only one line).
- You must have a tumor sample available from when your cancer spread.
- You need a smartphone (Android 8.0 or newer, or iOS 15.0 or newer) to use the study apps.
- Your heart function must be normal (LVEF at least 50%), and you must not have serious lung disease or a history of lung inflammation.
- If you have brain metastases, they must be small (≤2 cm) and stable, and you must be on a low dose of steroids if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted antibody-drug medicine (trastuzumab deruxtecan, T-DXd) in people with metastatic breast cancer that is HER2-low or HER2 IHC 0. It may help by treating tumors that haven’t previously received anti-HER2 treatment in the metastatic setting.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study is testing a new drug called trastuzumab deruxtecan (also known as T-DXd) in women with advanced breast cancer that is hormone receptor positive and has a very low level of HER2 (called HER2-ultralow). The trial aims to see if this drug can help shrink or slow the growth of the cancer in this specific group of patients.
This Phase 2 trial studies trastuzumab deruxtecan (T‑DXd) as a first treatment for people with HER2‑low, triple‑negative breast cancer that has spread or returned and cannot be fully removed by surgery. It aims to shrink tumors and control the disease while checking safety and side effects.
This study tests how well trastuzumab deruxtecan (T-DXd) works for people with HER2-low breast cancer that has spread. The treatment is given as part of routine care, and the trial uses advanced imaging (PET/CT) to measure response.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
Hear when a new Breast Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.